PredictAR™-pgx is an expanded comprehensive pharmacogenomics report providing guidance for over 120 medications. PredictAR™-pgx utilises the analysis of 18 genes, all of which play a role in the way patients respond to various medications.

Genes Tested

ABCB1, ABCC1, ABCG2, COMT, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DPYD, NUDT15, OPRM1, TPMT, SLCO1B1, UGT1A1, VKORC1

Clinical Specialties Benefited by PredictAR™-pgx Testing

Cardiology, Gastroenterology, General Practice, Haematology, Infectious Disease, Neurology, Oncology, Pain management, Psychiatry, Rheumatology, Transplantation, others

Result TAT

3-4 business days from receipt of sample

PredictAR™-pgx Test Report

Easily understood report that provides evidence-based expert recommendation by CPIC, FDA and DPGW.

PredictAR™-pgx provides both dosing suggestions and medication avoidance alerts. This information in-conjunction with clinical parameters, can be used by clinicians to ensure every patient receives a more personalised approach to medication selection.

Benefits of PredictAR™-pgx Pharmacogenomic Testing

• Up to 30% reduction in unwanted adverse drug reactions

• Improved medication efficacy

• Improved patient medication compliance